CPRX Takeover at $31.50 Under Legal Scrutiny; DCF Suggests Value Well Above Offer

What happened

Catalyst Pharmaceuticals agreed to be acquired by Angelini Pharma for $31.50 per share in cash, a 47% premium to the prior close but far below the ~$108 DCF intrinsic value estimated in the latest DeepValue report. Law firm Kahn Swick & Foti has launched an investigation into the fairness of the price and the sale process, signaling potential shareholder opposition. The report had rated CPRX a BUY based on a three-brand rare-disease portfolio, strong free cash flow, and a net cash balance sheet, with shares trading at ~12x earnings. The offer, while providing a near-term floor, crystallizes the risk that shareholders may not realize the company's full fundamental value. The investigation could lead to a higher bid, a breakup, or a shareholder lawsuit, introducing uncertainty into the thesis.

Implication

Long-term investors face a binary outcome: if the deal closes at $31.50, they exit at a fraction of intrinsic value; if the deal collapses, the stock likely reverts toward fundamental value (~$108 DCF) but with deal-break risk and potential volatility. The thesis shifts from a BUY on undervaluation to a speculative HOLD dependent on M&A outcome.

Thesis delta

The previous BUY thesis was predicated on fundamental undervaluation (P/E 12x, DCF $108) and a durable rare-disease franchise. The announced $31.50 acquisition introduces a material divergence: the offer is above market but well below intrinsic value, creating a conflict. The legal investigation suggests the price may be inadequate, and the thesis now hinges on whether a higher bid emerges or the deal fails. We move from BUY to HOLD/CAUTIOUS, as the upside case relies on a successful challenge or competing bid, not on organic execution.